AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8088611
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (iv)
Trial: 2779810
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg/h
Trial: 2779810
Drug: Buprenorphine 0.03
RxNorm normalized name: buprenorphine 0.035 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.03 mg/h
Trial: 1108581
Drug: 1.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 mg/kg of 0.5% plain bupivacaine
Trial: 1108581
Drug: 2.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6 mg/kg of 1.0% plain etidocaine
Trial: 27848196
Drug: LT4 oral
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 oral liquid formulation (SOL)
Trial: 27848196
Drug: LT4 tablet
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 tablet formulation (TAB)
Trial: 27848196
Drug: LT4 formulations
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 formulations (TAB and SOL)
Trial: 11029005
Drug: Supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised treatment interruptions (one or two)
Trial: 21962393
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (thalidomide plus dexamethasone)
Trial: 16382442
Drug: Ouabain infusion
RxNorm normalized name: ouabain
DrugBank: Ouabain (DB01092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ouabain infusion (0.4 mug.min(‐1).dl(‐1))
Trial: 16382442
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ouabain infusion)
Trial: 12805250
Drug: Enriched drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched drink with essential vitamins and minerals (30% to 150% of RDA and higher levels of antioxidants), taken twice a day for six months
Trial: 12805250
Drug: Placebo drink,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink, taken twice a day for six months
Trial: 12768686
Drug: Partial laryngectomy
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial laryngectomy with preoperative radiotherapy (dose 40-50Gy)
Trial: 12768686
Drug: Partial laryngectomy
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial laryngectomy with postoperative radiotherapy (dose 51-70 Gy)
Trial: 2065035
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg simvastatin q.a.m.
Trial: 2065035
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg simvastatin q.p.m.
Trial: 2065035
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg simvastatin q.a.m.
Trial: 2065035
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg simvastatin q.p.m.
Trial: 6127790
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with propantheline and antacids
Trial: 6127790
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with cimetidine and antacids
Trial: 6127790
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (unspecified)
Trial: 31780277
Drug: Standard-dose indometacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose indometacin (two 50 mg suppositories + placebo)
Trial: 31780277
Drug: High-dose indometacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose indometacin (three 50 mg suppositories + additional 50 mg after 4 hours)
Trial: 31780277
Drug: Standard-dose indometacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose indometacin
Trial: 31780277
Drug: High-dose indometacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose indometacin
Trial: 28093625
Drug: Ultralow dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow dose CT (0.13 ± 0.01 mSv)
Trial: 28093625
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CT (1.8 ± 0.7 mSv)
Trial: 26082615
Drug: Fimasartan/HCTZ 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan/HCTZ 12.5 mg
Trial: 22168805
Drug: 2.84 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.84 mL of lidocaine with epinephrine plus 0.5 M mannitol
Trial: 22168805
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of lidocaine with epinephrine plus 0.5 M mannitol
Trial: 22168805
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of lidocaine with epinephrine (control solution)
Trial: 22168805
Drug: Lidocaine with
RxNorm normalized name: Lidocaine with Tegaderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine with epinephrine formulations without mannitol
Trial: 3533085
Drug: suprofen 200
RxNorm normalized name: suprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprofen 200 mg/ml
Trial: 3533084
Drug: lysine acetylsalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lysine acetylsalicylate 0.9 g/2.5 ml
Trial: 30337745
Drug: Oxygen drive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen drive aerosol inhalation with 2 mg budesonide and 60 mg ambroxol for 3 days before operation
Trial: 30337745
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without preoperative aerosol inhalation
Trial: 30337745
Drug: Oxygen drive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen drive aerosol inhalation with 2 mg budesonide and 60 mg ambroxol
Trial: 27048692
Drug: Intra-arterial therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial therapy in patients without intravenous alteplase treatment
Trial: 27048692
Drug: Intra-arterial therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial therapy in patients with intravenous alteplase treatment
Trial: 24329132
Drug: Medium-dose ultrasound
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose ultrasound (1.5 Watt/cm(2))
Trial: 24329132
Drug: Low-dose ultrasound
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ultrasound (0.5 W/cm(2))
Trial: 18449450
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LPD) 0.6-0.8 g/kg per day
Trial: 18449450
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (NPD) 1.0-1.2 g/kg per day
Trial: 8618369
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate antacid tablets (Tums, 1000 mg)
Trial: 8618369
Drug: Famotidine (Pepcid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (Pepcid AC, 10 mg)
Trial: 1565534
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral cefixime (8 mg/kg)
Trial: 1565534
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily oral trimethoprim/sulfamethoxazole (TMP/SMX) (8/40 mg/kg/day)
Trial: 31564601
Drug: Tu Salud
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tu Salud ¡Si Cuenta! (Your Health Matters!) at Home Intervention, 6 monthly CHW visits
Trial: 29771700
Drug: IV amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amino acid supplementation (up to 100g daily to achieve 2.0g/kg/d)
Trial: 27278405
Drug: Polyphenol- and
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol- and fibre-rich foods (PFRF) - lower dose
Trial: 27278405
Drug: Polyphenol- and
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol- and fibre-rich foods (PFRF) - higher dose
Trial: 16084125
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg melatonin
Trial: 10713863
Drug: Rhinogen (hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhinogen (hyaluronic acid containing cream)
Trial: 10713863
Drug: H.E.C. (ointment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H.E.C. (ointment)
Trial: 7586621
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (5 micrograms/kg/min i.v. for a median of 109 hours)
Trial: 7586621
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (continued)
Trial: 7586621
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (continued and interrupted)
Trial: 1735342
Drug: Percutaneous drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous drainage using ultrasound guidance followed by intralesional nitroimidazole administration
Trial: 1735342
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy with nitroimidazoles
Trial: 20581302
Drug: Surgical management,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical management, radiation therapy, and systemic therapy for pelvic bone sarcomas
Trial: 17593235
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (0.2 U/kg)
Trial: 17593235
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (0.2 U/kg)
Trial: 17593235
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (0.4 U/kg)
Trial: 17593235
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (0.4 U/kg)
Trial: 2384192
Drug: 75-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-g oral glucose tolerance test (OGTT)
Trial: 2178521
Drug: Azelastine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 6 mg
Trial: 2178521
Drug: Azelastine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (all doses)
Trial: 22281416
Drug: Flexible(MIB) regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible(MIB) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Trial: 22281416
Drug: Flexible(APC) regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible(APC) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Trial: 22281416
Drug: Conventional 24/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 24/4 regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Trial: 20658805
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy only
Trial: 15310939
Drug: Emtricitabine-containing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine-containing treatment
Trial: 15310939
Drug: Once-daily abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily abacavir regimens
Trial: 15310939
Drug: Once-daily lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily lopinavir/ritonavir regimens
Trial: 15310939
Drug: Didanosine 400
RxNorm normalized name: didanosine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 400 mg/tenofovir regimens
Trial: 8553146
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg buserelin
Trial: 8553146
Drug: 3.6 mg
RxNorm normalized name: menthol 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg buserelin
Trial: 8553146
Drug: 7.2 mg
RxNorm normalized name: lysine 7.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2 mg buserelin
Trial: 2700103
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg in a single morning dose
Trial: 2700103
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg in a single nocte dose
Trial: 28007635
Drug: Integrated pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Integrated pharmaceutical care at a psychosocial intervention
Trial: 26653621
Drug: Renal artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal artery stent placement plus medical therapy
Trial: 22207522
Drug: Dorzolamide/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol fixed combination (DTFC) (2 × 1) for 4 weeks
Trial: 22207522
Drug: Brimonidine/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine/timolol fixed combination (BTFC) (2 × 1) for 4 weeks
Trial: 19630975
Drug: Protocolized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized treatment based on active and passive joint repositioning, stabilization exercises, stretching of the periarticular shoulder muscles and postural reeducation.
Trial: 19630975
Drug: Protocolized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized treatment with the addition of dry needling applied to active MTrPs.
Trial: 16485577
Drug: Withholding levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding levothyroxine before 131I therapy (Group G1.1)
Trial: 16485577
Drug: Withholding levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding levothyroxine before 131I therapy (Group G1.2)
Trial: 16485577
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of recombinant human thyrotropin without stopping levothyroxine (Group G2)
Trial: 15277271
Drug: BAY 38-3441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 38-3441 at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule)
Trial: 15277271
Drug: BAY 38-3441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 38-3441 at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule)
Trial: 11160951
Drug: Lamotrigine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (200 mg/day target maintenance dosage, adjusted from 100 to 500 mg/day)
Trial: 11160951
Drug: Valproate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (20 mg/kg/day target maintenance dosage, adjusted from 10 to 60 mg/kg/day)
Trial: 30519590
Drug: Fast administration
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast administration of 500ml balanced crystalloid fluid challenge (5-10 minutes)
Trial: 30519590
Drug: Slow administration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow administration of 500ml balanced crystalloid fluid challenge (20-30 minutes)
Trial: 30519590
Drug: Fast administration
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast administration
Trial: 30519590
Drug: Slow administration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow administration
Trial: 20831535
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg (RAC)
Trial: 20831535
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg (EAC)
Trial: 19024254
Drug: 1% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% CHX varnish applied once daily for 3 consecutive days (Group B)
Trial: 19024254
Drug: Placebo varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo varnish applied once daily for 3 consecutive days (Group D)
Trial: 16458191
Drug: High phenolic
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High phenolic content olive oil (366 mg/kg)
Trial: 16458191
Drug: Moderate phenolic
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate phenolic content olive oil (164 mg/kg)
Trial: 16458191
Drug: Low phenolic
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low phenolic content olive oil (2.7 mg/kg)
Trial: 10573065
Drug: Basiliximab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (40 mg total: 20 mg on days 0 and 4)
Trial: 9339962
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists, antacids, sucralfate, pirenzepine
Trial: 3728212
Drug: Terbutaline (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (intravenous administration for 5 hours)
Trial: 3728212
Drug: Isoprenaline (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (intravenous administration for 5 hours)
Trial: 3728212
Drug: Terbutaline (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (oral administration for 24 days)
Trial: 30834639
Drug: Neuromuscular blocking
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blocking agent first
Trial: 30834639
Drug: Sedative agent
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative agent first
Trial: 20140897
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g isomaltulose
Trial: 20140897
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g sucrose
Trial: 17650803
Drug: RT combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT combined with oral TCM from the start of RT till 5 weeks after RT
Trial: 9430135
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (amino acid mixture containing 2.3 g of tryptophan)
Trial: 7655769
Drug: Profinal (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profinal (600 mg)
Trial: 7655769
Drug: Brufen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brufen (600 mg)
Trial: 2571061
Drug: OM756 alpha
RxNorm normalized name: Alpha Arbutin
DrugBank: alpha-Arbutin (DB14109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM756 alpha 10 mg propranolol 'Inderal' tablet
Trial: 2571061
Drug: Generic 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic 10 mg propranolol tablet
Trial: 1099176
Drug: 4000 mg
RxNorm normalized name: talc 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 mg of ascorbic acid administered 27 and 3 hours prior to assessment
Trial: 1099176
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of ascorbic acid administered in the same manner
Trial: 23065145
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir (TFV)
Trial: 23065145
Drug: Daily topical
RxNorm normalized name: Clindagel 1 % Once-Daily Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical tenofovir (TFV) vaginal gel
Trial: 23065145
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral tablet and vaginal gel
Trial: 16449754
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitor treatment (AD+ChEI)
Trial: 16449754
Drug: No Cholinesterase
RxNorm normalized name: cholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Cholinesterase inhibitor treatment (AD‐ChEI)
Trial: 15339677
Drug: Adverse cytogenetics
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse cytogenetics and white blood cell count ≥20 yen 10^9/L at diagnosis
Trial: 8187315
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin infusion (60 mU/kg/h)
Trial: 8187315
Drug: Low insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low insulin infusion (15 mU/kg/h)